Study Shows Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination
A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effective tool for achieving adherence in well more than half of such cases, reports Business Wire.
This research, sponsored by ResMed (NYSE: RMD, ASX: RMD), was presented this week at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
Patients diagnosed with sleep apnea are usually prescribed a PAP device that provides either continuous (CPAP) or auto-adjusting (APAP) pressure. A bilevel device delivers two distinct pressures, one for inhalation and one for exhalation. Physicians may prescribe bilevel for patients who are pressure intolerant or have continued evidence of apnea at higher pressures.
from Sleep Review http://www.sleepreviewmag.com/2018/06/study-switching-bilevel-pap-patients-therapy-termination/